Personalized medicine is the future of medical practice. In oncology, tumor heterogeneity assessment represents a pivotal step for effective treatment planning and prognosis prediction. Despite new procedures for DNA sequencing and analysis, non-invasive methods for tumor characterization are needed to impact on daily routine. On purpose, imaging texture analysis is rapidly scaling, holding the promise to surrogate histopathological assessment of tumor lesions. In this work, we propose a tree-based representation strategy for describing intra-tumor heterogeneity of patients affected by metastatic cancer. We leverage radiomics information extracted from PET/CT imaging and we provide an exhaustive and easily readable summary of the disease spreading. We exploit this novel patient representation to perform cancer subtyping according to hierarchical clustering technique. To this purpose, a new heterogeneity-based distance between trees is defined and applied to a case study of prostate cancer. Clusters interpretation is explored in terms of concordance with severity status, tumor burden and biological characteristics. Results are promising, as the proposed method outperforms current literature approaches. Ultimately, the proposed method draws a general analysis framework that would allow to extract knowledge from daily acquired imaging data of patients and provide insights for effective treatment planning.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666477PMC
http://dx.doi.org/10.1038/s41598-022-23752-2DOI Listing

Publication Analysis

Top Keywords

intra-tumor heterogeneity
8
effective treatment
8
treatment planning
8
proposed method
8
imaging-based representation
4
representation stratification
4
stratification intra-tumor
4
heterogeneity tree-edit
4
tree-edit distance
4
distance personalized
4

Similar Publications

Article Synopsis
  • Gastric cancer has a poor prognosis and varied cellular characteristics, highlighting the need for a better understanding of its tumor microenvironment and heterogeneity to create effective treatments.
  • Researchers analyzed single-cell RNA sequencing data and used machine learning to identify 18 significant genes related to gastric cancer, with a particular focus on NFKBIE, which showed a strong correlation with patient risk levels.
  • The study suggests NFKBIE could serve as a potential biomarker and therapeutic target, with certain drugs like gemcitabine and chloropyramine possibly being effective against high-risk gastric cancer patients.
View Article and Find Full Text PDF

Genomics Review of Selective RET Inhibitors Sensitivity in Thyroid Cancer Clinical Trials.

Am J Med Genet C Semin Med Genet

January 2025

Gastrointestinal and Endocrine Tumor Unit, Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.

RET gene is a driver of thyroid cancer (TC) tumorigenesis. The incidence of TC has increased worldwide in the last few decades, both in medullary and follicular-derived subtypes. Several drugs, including multikinase and selective inhibitors, have been explored.

View Article and Find Full Text PDF
Article Synopsis
  • Low intra-tumor heterogeneity (ITH) is linked to better patient survival and response to immunotherapy, but the role of immune factors in tumor aggressiveness remains unclear.
  • Researchers studied immune escape mechanisms in mouse tumors with low ITH, finding non-rejected clones had more tumor-associated macrophages and T-cell exhaustion compared to rejected ones.
  • They identified Mif as a key factor in immune rejection; knocking it out led to smaller tumors and lower macrophage infiltration, a finding that was supported by data from melanoma patients.
View Article and Find Full Text PDF

A Current Perspective of Medical Informatics Developments for a Clinical Translation of (Non-coding)RNAs and Single-Cell Technologies.

Methods Mol Biol

December 2024

Institute for Medical Informatics and Biometry, Faculty of Medicine Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.

The journey from laboratory research to clinical practice is marked by significant advancements in the fields of single-cell technologies and non-coding RNA (ncRNA) research. This convergence may reshape our approach to personalized medicine, offering groundbreaking insights and treatments in various clinical settings. This chapter discusses advancements in (nc)RNAs in the clinics, innovations in single-cell technologies and algorithms, and the impact on actual precision medicine, showing the integration of single-cell and ncRNA research can have a tangible impact on precision medicine.

View Article and Find Full Text PDF

Urinary bladder cancer (UBC) is the ninth most common cancer worldwide. The intra-tumor heterogeneity of the UBC microenvironment explains the variances in response to therapy among patients. Tumor immune microenvironment (TIME) is based on the balance between anti-tumor and pro-tumorigenic immunity that eventually determines the tumor fate.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!